Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet
However, manufacturing companies, including Novo Nordisk and Eli Lilly, do not guarantee the sterility of GLP-1 drugs like semaglutide and tirzepatide beyond the expiration date
Either outcome will directly impact BPI Labs ability to continue producing compounded semaglutide at scale
It comes as no surprise: The Centers for Disease Control and Prevention (CDC) estimates that 42% of Americans live with obesity
October 24, 2022
You can get nauseous if you try to eat as much as usual while taking Semaglutide
